120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
丝状噬菌体在非小细胞肺癌及脑转移治疗中的应用：近期前景
Authors Xu S, Liang P, Zhang G, Fu X, Wang Y
Received 4 July 2025
Accepted for publication 15 December 2025
Published 20 January 2026 Volume 2026:21 551541
DOI https://doi.org/10.2147/IJN.S551541
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Kamakhya Prakash Misra
Songbai Xu,1 Peiyi Liang,2 Guangxin Zhang,3,* Xiying Fu,4,* Yicun Wang2,*
1Department of Neurosurgery, First Hospital of Jilin University, Changchun, People’s Republic of China; 2Department of Medical Research Center, Second Hospital of Jilin University, Changchun, People’s Republic of China; 3Department of Thoracic Surgery, Second Hospital of Jilin University, Changchun, People’s Republic of China; 4Department of Endocrinology, Second Hospital of Jilin University, Changchun, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yicun Wang, Email wangyicun@jlu.edu.cn Xiying Fu, Email fuxiying@jlu.edu.cn
Abstract: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with brain metastases occurring in 24% to 40% of advanced NSCLC patients and a poor prognosis. Traditional treatment methods for brain metastases, such as surgery and radiotherapy, often result in neurocognitive impairment and brain edema. Furthermore, chemotherapy drugs struggle to penetrate the central nervous system. Third-generation EGFR-TKI drugs that can cross the blood–brain barrier have demonstrated efficacy in treating NSCLC patients with brain metastases, but their benefits are limited to those with specific driver genes. Immunotherapy demonstrated potential in the treatment of NSCLC patients with brain metastases, although the adverse events limited its clinical use. Given these limitations, filamentous phages emerge as a promising bio-nanomaterial due to their unique biosafety profile, high solubility, and ability to facilitate targeted delivery, which can potentially minimize systemic toxicity. This review focuses on two core applications of filamentous phages in NSCLC and brain metastasis therapy: (i) phage display-derived targeting peptides and (ii) intact engineered filamentous phages as delivery scaffolds. As delivery systems, filamentous phages can prolong in vivo circulation time, reduce toxicity, and effectively cross the Blood–Brain Barrier (BBB)—evidences include filamentous phage mediating targeted delivery of chemotherapeutics and siRNA to NSCLC cells, and phage-nanomaterial hybrids enhancing tumor accumulation. The review also elaborates on the clinical translation potential of filamentous phages, including personalized therapy via patient-specific peptide screening, and discusses current limitations. Filamentous phage-based nanocarriers are expected to improve the quality of life of NSCLC patients with brain metastases.
Keywords: filamentous phage, lung cancer, brain metastases, nanoparticles, NSCLC
1Department of Neurosurgery, First Hospital of Jilin University, Changchun, People’s Republic of China; 2Department of Medical Research Center, Second Hospital of Jilin University, Changchun, People’s Republic of China; 3Department of Thoracic Surgery, Second Hospital of Jilin University, Changchun, People’s Republic of China; 4Department of Endocrinology, Second Hospital of Jilin University, Changchun, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yicun Wang, Email wangyicun@jlu.edu.cn Xiying Fu, Email fuxiying@jlu.edu.cn
Abstract: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with brain metastases occurring in 24% to 40% of advanced NSCLC patients and a poor prognosis. Traditional treatment methods for brain metastases, such as surgery and radiotherapy, often result in neurocognitive impairment and brain edema. Furthermore, chemotherapy drugs struggle to penetrate the central nervous system. Third-generation EGFR-TKI drugs that can cross the blood–brain barrier have demonstrated efficacy in treating NSCLC patients with brain metastases, but their benefits are limited to those with specific driver genes. Immunotherapy demonstrated potential in the treatment of NSCLC patients with brain metastases, although the adverse events limited its clinical use. Given these limitations, filamentous phages emerge as a promising bio-nanomaterial due to their unique biosafety profile, high solubility, and ability to facilitate targeted delivery, which can potentially minimize systemic toxicity. This review focuses on two core applications of filamentous phages in NSCLC and brain metastasis therapy: (i) phage display-derived targeting peptides and (ii) intact engineered filamentous phages as delivery scaffolds. As delivery systems, filamentous phages can prolong in vivo circulation time, reduce toxicity, and effectively cross the Blood–Brain Barrier (BBB)—evidences include filamentous phage mediating targeted delivery of chemotherapeutics and siRNA to NSCLC cells, and phage-nanomaterial hybrids enhancing tumor accumulation. The review also elaborates on the clinical translation potential of filamentous phages, including personalized therapy via patient-specific peptide screening, and discusses current limitations. Filamentous phage-based nanocarriers are expected to improve the quality of life of NSCLC patients with brain metastases.
Keywords: filamentous phage, lung cancer, brain metastases, nanoparticles, NSCLC